Navigation Links
Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has closed its sale and leaseback agreement with Veralliance Properties for its real estate assets. Total consideration received by Neurocrine for the properties was $109 million. Concurrently with the closing of the transaction, Neurocrine leased back its corporate headquarters for a 12 year term, with renewal options. Neurocrine also has certain options under the lease to repurchase all of the properties included in the transaction at certain times during lease period. Under the terms of the asset purchase agreement, Neurocrine will receive cash of approximately $61 million net of fees, expenses and existing indebtedness.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, pain, and diabetes. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general. Other risks are described in the Company's report on Form 10-K for the year ended December 31, 2006 and Form 10-Q for the quarter ended September 30, 2007. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... last long after their final treatments. Physician researchers at The Marcus Institute ... a mind-body therapy, for efficacy in reducing symptoms of traumatic stress in cancer ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is proud ... their network through his work at BKP Chiropractic in Lancaster . ... degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 Cryoablation, Electrical, ... The global ablation technologies market is expected to grow ... from 2022-2027. The market is expected to grow at a CAGR ... $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
Breaking Medicine Technology: